无码影视中文高清_亚洲天堂光棍影院_欧美激情欧美激情在线五月_国产精品日韩免费观看_一级黄色毛片成人影院_六月综合激情_亚洲av无码区国产乱码粉嫩_无遮挡免费视频_97操射操射人人色_可以免费观看的黄色完整版网站视频

掃碼關注公眾號           掃碼咨詢技術支持           掃碼咨詢技術服務
  
客服熱線:400-901-9800  客服QQ:4009019800  技術答疑  技術支持  質(zhì)量反饋  人才招聘  關于我們  聯(lián)系我們
完美世界有声小说,小说排行榜
首頁 > 產(chǎn)品中心 > 一抗 > 產(chǎn)品信息
Rabbit Anti-MSH6  antibody (bs-3804R)  
~~~促銷代碼KT202411~~~
訂購熱線:400-901-9800
訂購郵箱:sales@bioss.com.cn
訂購QQ:  400-901-9800
技術支持:techsupport@bioss.com.cn
說明書: 50ul  100ul  200ul
50ul/1180.00元
100ul/1980.00元
200ul/2800.00元
大包裝/詢價

產(chǎn)品編號 bs-3804R
英文名稱 Rabbit Anti-MSH6  antibody
中文名稱 錯配修復蛋白6抗體
別    名 DNA mismatch repair protein MSH6; G/T mismatch binding protein; GTBP; GTMBP; HNPCC 5; HNPCC5; HSAP; MSH 6; mutS (E. coli) homolog 6; MutS alpha 160 kDa subunit; mutS homolog 6; p160; Sperm associated protein; MSH6_HUMAN; MutS Protein Homolog 6.  
Specific References  (1)     |     bs-3804R has been referenced in 1 publications.
[IF=14.919] Yen, Yu-Ting. et al. Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response. Nat Commun. 2021 Dec;12(1):1-14  WB ;  Mous,Human.  
研究領域 腫瘤  免疫學  轉(zhuǎn)錄調(diào)節(jié)因子  
抗體來源 Rabbit
克隆類型 Polyclonal
交叉反應 Human,Rat (predicted: Mouse,Rabbit,Pig,Sheep,Cow,Dog)
產(chǎn)品應用 WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量 153kDa
細胞定位 細胞核 
性    狀 Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated synthetic peptide derived from human MSH6: 812-910/1360 
亞    型 IgG
純化方法 affinity purified by Protein A
緩 沖 液 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
保存條件 Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
注意事項 This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed PubMed
產(chǎn)品介紹 This gene encodes a member of the DNA mismatch repair MutS family. In E. coli, the MutS protein helps in the recognition of mismatched nucleotides prior to their repair. A highly conserved region of approximately 150 aa, called the Walker-A adenine nucleotide binding motif, exists in MutS homologs. The encoded protein heterodimerizes with MSH2 to form a mismatch recognition complex that functions as a bidirectional molecular switch that exchanges ADP and ATP as DNA mismatches are bound and dissociated. Mutations in this gene may be associated with hereditary nonpolyposis colon cancer, colorectal cancer, and endometrial cancer. Transcripts variants encoding different isoforms have been described. [provided by RefSeq, Jul 2013]

Function:
Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MSH2 to form MutS alpha, which binds to DNA mismatches thereby initiating DNA repair. When bound, MutS alpha bends the DNA helix and shields approximately 20 base pairs, and recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. After mismatch binding, forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair.

Subunit:
Heterodimer consisting of MSH2-MSH6 (MutS alpha). Forms a ternary complex with MutL alpha (MLH1-PMS1). Interacts with EXO1. Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex. This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains. Interacts with ATR.

Subcellular Location:
Nucleus.

Post-translational modifications:
The N-terminus is blocked.
Phosphorylated upon DNA damage, probably by ATM or ATR.
Phosphorylated by PRKCZ, which may prevent MutS alpha degradation by the ubiquitin-proteasome pathway.

DISEASE:
Defects in MSH6 are the cause of hereditary non-polyposis colorectal cancer type 5 (HNPCC5) [MIM:600678]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. MSH6 mutations appear to be associated with atypical HNPCC and in particular with development of endometrial carcinoma or atypical endometrial hyperplasia, the presumed precursor of endometrial cancer. Defects in MSH6 are also found in familial colorectal cancers (suspected or incomplete HNPCC) that do not fulfill the Amsterdam criteria for HNPCC.

Similarity:
Belongs to the DNA mismatch repair MutS family.
Contains 1 PWWP domain.

SWISS:
P52701

Gene ID:
2956

Database links:

Entrez Gene: 2956 Human

Entrez Gene: 17688 Mouse

Entrez Gene: 100360342 Rat

Omim: 600678 Human

SwissProt: P52701 Human

SwissProt: P54276 Mouse

Unigene: 445052 Human

Unigene: 18210 Mouse



MSH6是DNA錯配修復系統(tǒng)的基因組成之一。DNA錯配修復系統(tǒng)由hMLH1,hMSH2,hPMS1,hPMS2,hMSH6和hMSH3等基因組成,這套系統(tǒng)的存在,可保證遺傳物質(zhì)的完整性和穩(wěn)定性,避免遺傳物質(zhì)的突變產(chǎn)生,保證DNA復制的高保真度。
產(chǎn)品圖片
Sample: U87MG(Human) Cell Lysate at 30 ug Molt-4(Human) Cell Lysate at 30 ug Primary: Anti- MSH6 (bs-3804R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 153 kD Observed band size: 120/121 kD
Sample: 293T(Human) Cell Lysate at 30 ug A431(Human) Cell Lysate at 30 ug Primary: Anti- MSH6 (bs-3804R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 153 kD Observed band size: 121 kD
Paraformaldehyde-fixed, paraffin embedded (Human colon carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (MSH6) Polyclonal Antibody, Unconjugated (bs-3804R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (Rat colon); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (MSH6) Polyclonal Antibody, Unconjugated (bs-3804R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
版權所有 2004-2026 xiaowangchong.cn 北京博奧森生物技術有限公司
通過國際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號: 00124Q34771R2M/1100
通過國際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號: CQC24QY10047R0M/1100
京ICP備05066980號-1         京公網(wǎng)安備110107000727號